The differences observed between CHIP in MM and NHL are potentially related to the shorter duration of chemotherapy exposure in patients receiving induction therapy for MM and less use of DNA damaging agents that may select for specific mutant clones. Here, STUB1 is linked to Miyoshi myopathy.